Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical research trials and A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years. A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years clinical trial. Participants frequently obtain the most expert healthcare available for their A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years



A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years

For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 2 Years/18 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - (All of these criteria must be met in order to be eligible to participate in this study) - Females of child-bearing potential must have a negative pregnancy test at screening and on Day 1 and must agree to use a proven barrier method of contraception (e.g., spermicide plus condom). Note: hormonal contraceptives (e.g., birth control pills, Norplant, etc.) are not considered a sufficient form of contraception for this study. - Parent or legal guardian (and study patient if possible) has the ability to understand what is required of the patient in the study, what will occur during the study, and provide written informed consent to participate. - Screening lab result of plasma HIV-1 RNA greater than or equal to 400 copies/mL. - Must be able to use 2 nucleoside reverse transcriptase inhibitors as a background regimen. - Exclusion Criteria: - No prior history of having received AGENERASE. - No use of non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy within 14 days of study Day 1 or anticipated need for concurrent NNRTI therapy during the study period. - Cannot have had an AIDS defining illness (acute CDC Category C event) within 28 days of screening. - Cannot be pregnant or breast-feeding. - Additional qualifying criteria to be determined by the physician.
Total Enrollment: 

Location and Contact Information:

Study Site
Milan,  ,  20122
Italy
 

Study Site
Madrid,  ,  28046
Spain
 

Study Site
Richmond,  Virginia,  23219
United States
 

Study Site
Verona,  ,  37126
Italy
 

Study Site
Modena,  ,  41100
Italy
 

Study Site
New York City,  New York,  10016
United States
 

Study Site
Chicago,  Illinois,  60614
United States
 

Study Site
Cleveland,  Ohio,  44106
United States
 

Study Site
Bucharest,  , 
Romania
 

Study Site
London,  ,  WC1N 1EH
United Kingdom
 

Study Site
New York City,  New York,  10021
United States
 

Study Site
Los Angeles,  California,  90033
United States
 

Study Site
Milan,  ,  20142
Italy
 

Study Site
Bucharest,  , 
Romania
 

Study Site
Genoa,  ,  16147
Italy
 

Study Site
Malaga,  ,  29010
Spain
 

Study Site
Padua,  ,  35128
Italy
 

Study Site
Rome,  ,  00165
Italy
 

Study Site
Chapel Hill,  North Carolina,  27599
United States
 

Study Site
Syracuse,  New York,  13120
United States
 

Study Site
St. Petersburg,  Florida,  33701
United States
 

Study Site
Durham,  North Carolina,  27705
United States
 

Study Site
Cordoba,  ,  14004
Spain
 

Study Site
Amadora,  ,  2700-276
Portugal
 

Study Site
Bucharest,  , 
Romania
 

Study Site
London,  ,  W2 1NY
United Kingdom
 

Study Site
Barcelona,  ,  08950
Spain
 

Study Site
Lisbon,  ,  1150
Portugal
 

Study Site
Barcelona,  ,  08035
Spain
 

Study Site
Los Angeles,  California,  90027
United States
 

Study Site
Stony Brook,  New York,  11794
United States
 

Study Site
Lisboa,  ,  1649-035
Portugal
 

Study Site
Montreal,  Quebec,  H3T 1C5
Canada
 

Study Site
Florence,  ,  50132
Italy
 

Study Site
Ft. Worth,  Texas,  76104
United States
 

Study Site
Toronto,  Ontario,  M5G 1X8
Canada
 

Study Site
New Orleans,  Louisiana,  70112
United States
 

Study Site
Boston,  Massachusetts,  02118
United States
 

Study Site
Birmingham,  Alabama,  35233
United States
 

Study Site
Bronx,  New York,  10461
United States
 

Study Site
Jacksonville,  Florida,  32209
United States
 

Study Site
Seville,  ,  410113
Spain
 

Study Site
Pavia,  ,  27100
Italy
 

Study Site
New York City,  New York,  10029
United States
 

Study Site
Rotterdam,  ,  3015 GJ
Netherlands
 

Study Site
Dallas,  Texas,  75235
United States
 

Study Site
London,  ,  SW17 0QT
United Kingdom
 

Study Site
Madrid,  ,  28007
Spain
 

Study Site
Madrid,  ,  28041
Spain
 


Additional Information:
Study ID Numbers:
  APV 20003; 
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040664

Other Hiv Infections Studies:
1. The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

2. Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

3. A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS

4. Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Related Studies:

Other HIV Infections Clinical Trials
Other Clinical Trials
Other Madrid Clinical Trials

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years

Modify your Search

  Other HIV Infections Clinical Trials
  Other Clinical Trials
  Other Madrid Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103